Page 16 - Clinical Program News Today

Initial data from Phase 1 combination with capecitabine in advanced ovarian cancer are expected in mid-2023 Dose for the Phase 1 combination trials identified as 400mg daily Ended 2022 with... | March 23, 2023

CAMBRIDGE, Mass., March 21, 2023 -- Intellia Therapeutics, Inc. , a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based... | March 21, 2023

● Type D Meeting Requested to Accelerate XRx-008 Clinical Program ● CALGARY, Alberta, March 14, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc....

- Achieved more than half of enrollment in U.S. SAVVE pivotal trial of VenoValve® in 2022- Multiple near-term milestones expected across VenoValve® and enVVe clinical programs- Ended the year with $39.1

Anti-Human trafficking experts said Florida is getting "some things right" in the fight against child/youth sex trafficking, but there is room for improvement.

We asked several healthcare executives to share their digital pharmacy predictions and trends to watch in 2023 and beyond.

Study successfully identified lowest effective dose1.0% formulation reached primary endpoint with statistical significanceCompany preparing for End of Phase 2 meeting with FDA following full analysisTORONTO

Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema - read this article along with other careers information, tips and advice on BioSpace

A special intervention program almost completely eliminated the number of suicides among those who attempted it at least ...

Outside Biostatisticians with Specific Expertise in Alzheimer’s Disease Will Conduct an Independent Statistical Analysis on The Clinical Dataset. Clinical...